Undisclosed · Other round · AI · Birkirkara, Malta
Birkirkara-based EBO has secured an undisclosed investment from Olea Venture Partners to expand its AI-powered patient-engagement platform across Europe and the United States. EBO says the capital will accelerate adoption across health systems and healthcare providers, support new clinical and operational workflows and fund international expansion.
Patient administration is the product surface
EBO automates patient interactions including appointment management, self-assessments and communications across care pathways. Its platform connects with healthcare information systems and communicates through channels including email, SMS, social messaging, chat and speech.
The commercial mechanism is less about offering a general-purpose chatbot than embedding automation inside an existing patient workflow. A hospital can use the software to validate a waiting list, manage a booking or collect information before an appointment, while keeping the interaction connected to the system that staff already use. That can release administrative capacity when adoption is high, but it also makes integration, governance and implementation part of the product rather than work that ends after a software sale.
EBO reports commercial operations in the UK, Italy, Greece and Malta, with 24 live deployments across UK NHS Trusts and hospitals. Olea says patient adoption has reached as high as 97% in some deployments and customer returns have reached up to 5x. Those figures are investor-reported rather than independently audited here, but they explain why Olea describes the next phase as scaling a model that has already been deployed.
Expansion depends on making deployments repeatable
Olea is backed by the European Investment Fund and supported by EquiFund II. The investor says it will help EBO deepen UK adoption, strengthen its presence in Southeast Europe and enter the US, focusing on health-system partnerships, commercial strategy and a repeatable international expansion model.
EBO's appointment to the UK's G-Cloud 15 framework in August gives eligible public-sector organisations an established procurement route to its software, subject to individual call-off agreements. That lowers one barrier to customer access, but it does not remove the work of integrating with clinical systems, adapting workflows and demonstrating safe, measurable outcomes.
The investment therefore backs a shift from proving individual deployments to repeating them across more institutions and markets. EBO can reuse its underlying conversational and workflow technology, but each health system brings its own procurement, integration and governance requirements. The company's growth will depend on how much of that implementation can be standardised without losing the safeguards and local fit that healthcare customers require.
